Trial
NCT02231580
Study Exploring Safety, Pharmacokinetic and Pharmacodynamic of BN82451 in Male Huntington's Disease Patients
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Ipsen
Collaborators
—
Condition
Huntington's Disease
Intervention
BN82451B
Why stopped
The study was terminated due to subject recruitment problems.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-01-15